Research in non-small cell lung cancer seems to be moving at breakneck pace, bringing with it new clinical data that could drastically change the standard of care. In November, MD /alert covered a number of journal studies, FDA developments, and conference presentations on NSCLC.
We’ve compiled a list of the most significant research reported on this month.
.jpg)
Doctor writing prescription. Source: Getty
Nivolumab Plus Low-Dose Ipilimumab, Chemotherapy Improves OS in NSCLC Patients
“We are excited by the CheckMate -9LA results, which demonstrate the potential of [nivolumab] plus low-dose [ipilimumab] to provide a survival benefit to patients with non-small cell lung cancer in the first-line setting when administered concomitantly with a limited course of chemotherapy,” Fouad Namouni, MD, said… READ MORE.
Durvalumab, Tremelimumab and Chemotherapy Combo Improves PFS in NSCLC
“The POSEIDON trial provides evidence of the efficacy of [durvalumab] in patients with stage IV non-small-cell lung cancer,” José Baselga, MD, PhD, noted… READ MORE.
Combination Pegilodecakin with Anti-PD-1 Monoclonal Antibody Inhibitors Demonstrates Safety, OR for NSCLC
A Study in The Lancet Oncology found that pegilodecakin with anti-programmed cell death protein 1 (PD-1) may be a viable therapy for patients with non-small-cell lung cancer… READ MORE.
FLAURA: Patients with NSCLC on Osimertinib Have Improved OS Compared with Gefitinib, Erlotinib
A look back at ESMO 2019 highlights data presented on the phase III FLAURA trial, showing that patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer receiving osimertinib showed clinically meaningful overall survival… READ MORE.
Lorlatinib Demonstrates Clinical Activity in ROS1-Positive NSCLC
A new, investigational agent demonstrated clinical activity in patients with the disease, including those with central nervous system metastases and those previously treated with crizotinib… READ MORE.
